Basilea Pharmaceutica AG

LSE:0QNA Stock Report

Market Cap: CHF 510.3m

Basilea Pharmaceutica Management

Management criteria checks 3/4

Basilea Pharmaceutica's CEO is David Veitch, appointed in Apr 2018, has a tenure of 6.58 years. total yearly compensation is CHF1.75M, comprised of 35% salary and 65% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth CHF54.76K. The average tenure of the management team and the board of directors is 6.8 years and 9.6 years respectively.

Key information

David Veitch

Chief executive officer

CHF 1.7m

Total compensation

CEO salary percentage35.0%
CEO tenure6.6yrs
CEO ownership0.01%
Management average tenure6.8yrs
Board average tenure9.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Veitch's remuneration changed compared to Basilea Pharmaceutica's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CHF 652k

Mar 31 2024n/an/a

CHF 5m

Dec 31 2023CHF 2mCHF 611k

CHF 10m

Sep 30 2023n/an/a

CHF 33m

Jun 30 2023n/an/a

CHF 56m

Mar 31 2023n/an/a

CHF 34m

Dec 31 2022CHF 2mCHF 599k

CHF 12m

Sep 30 2022n/an/a

CHF 6m

Jun 30 2022n/an/a

CHF 851k

Mar 31 2022n/an/a

-CHF 3m

Dec 31 2021CHF 2mCHF 594k

-CHF 7m

Sep 30 2021n/an/a

-CHF 26m

Jun 30 2021n/an/a

-CHF 45m

Mar 31 2021n/an/a

-CHF 30m

Dec 31 2020CHF 1mCHF 589k

-CHF 15m

Sep 30 2020n/an/a

-CHF 6m

Jun 30 2020n/an/a

CHF 3m

Mar 31 2020n/an/a

-CHF 10m

Dec 31 2019CHF 1mCHF 583k

-CHF 22m

Sep 30 2019n/an/a

-CHF 23m

Jun 30 2019n/an/a

-CHF 24m

Mar 31 2019n/an/a

-CHF 28m

Dec 31 2018CHF 2mCHF 529k

-CHF 31m

Compensation vs Market: David's total compensation ($USD1.97M) is above average for companies of similar size in the UK market ($USD983.02K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Veitch (59 yo)

6.6yrs

Tenure

CHF 1,745,679

Compensation

Mr. David Veitch has been the Chief Executive Officer of Basilea Pharmaceutica Ltd. since April 19, 2018 and Basilea Pharmaceutica International Ltd., since September 1, 2014. Mr. Veitch joined Basilea in...

Leadership Team

NamePositionTenureCompensationOwnership
David Veitch
Chief Executive Officer6.6yrsCHF 1.75m0.011%
CHF 54.8k
Adesh Kaul
Chief Financial Officer5.6yrsno data0.0041%
CHF 21.1k
Gerrit Hauck
Chief Technology Officer6.5yrsno datano data
Laurenz Kellenberger
Chief Scientific Officer15.8yrsno data0.0041%
CHF 21.1k
Marc Engelhardt
Chief Medical Officer6.8yrsno datano data
Peer Schroder
Head of Corporate Communications & Investor Relationsno datano datano data
Damian Heller
General Counsel & Corporate Secretary7.3yrsno datano data
Andreas Kumin
Head of Corporate Developmentno datano datano data
Ursula Eberhardt
Head of Global Human Resources7.8yrsno datano data
Mark Jones
Head of Global Affairs6.8yrsno datano data
Peter Bielmeier
Head of Global Quality Management2.2yrsno datano data
Mohammed Benghezal
Head of Biologyno datano datano data

6.8yrs

Average Tenure

58yo

Average Age

Experienced Management: 0QNA's management team is seasoned and experienced (6.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nicole Onetto
Independent Non-Executive Director7.6yrsCHF 192.13k0.0061%
CHF 31.0k
Leonard Kruimer
Independent Non-Executive Director2.6yrsCHF 186.88kno data
Domenico Scala
Independent Chairman of the Board13yrsCHF 337.68k0.0049%
CHF 24.9k
Alf Gunnar Nicklasson
Independent Non-Executive Director11.6yrsCHF 211.75k0.015%
CHF 74.0k
Carole Sable
Independent Non-Executive Director1.6yrsCHF 192.13kno data
Thomas Werner
Independent Vice-Chairman13yrsCHF 224.80k0.0098%
CHF 50.2k

9.6yrs

Average Tenure

67yo

Average Age

Experienced Board: 0QNA's board of directors are considered experienced (9.6 years average tenure).